Screener
Neurocrine Biosciences NBIX Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Neurocrine Biosciences in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The source filing: Neurocrine Biosciences’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000914475-26-000026
| (in millions) | March 31,2026 | December 31,2025 |
|---|---|---|
| Sales rebates and reserves | $231.3 | $226.0 |
| Current income taxes payable | 186.4 | 68.0 |
| Accrued development costs | 110.7 | 101.3 |
| Accrued employee related costs | 81.7 | 128.8 |
| Current branded prescription drug fee | 42.9 | 45.3 |
| Accounts payable and other accrued liabilities | 120.0 | 104.9 |
| Total accounts payable and accrued liabilities | $773.0 | $674.3 |
Item 1. Financial Statements
FAQ
- What is Neurocrine Biosciences's accrued expenses?
- Neurocrine Biosciences (NBIX) reported accrued expenses of $81.7M in Q1 2026.
- How has Neurocrine Biosciences's accrued expenses changed year-over-year?
- Neurocrine Biosciences's accrued expenses increased by 42.1% year-over-year, from $57.5M to $81.7M.
- What is the long-term trend for Neurocrine Biosciences's accrued expenses?
- Over 5 years (2020 to 2025), Neurocrine Biosciences's accrued expenses has grown at a 48.6% compound annual growth rate (CAGR), from $17.8M to $128.8M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Neurocrine Biosciences's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude